ALTO-100 PO tablet for Post-Traumatic Stress Disorder

"This particular research study necessitates that participants are aged between 18 and 69. For patients below the age of consent, there are 434 studies available to them whereas 1668 can be found for seniors past 65 years old."

"Patients can find this particular trial at Site 137 in Noblesville, Indiana and Site 142 in Lincoln, Nebraska. Additionally, there are 21 other sites scattered about the country - including one located in Mather California."

"Our team at Power gives ALTO-100 PO tablet a rating of 2 on the safety scale, as it has not gone through Phase 3 trials yet and thus lacks clinical evidence to support its efficacy."

"As detailed on clinicaltrials.gov, this particular research has stopped accepting participants; the initial post was made December 9th 2021 and last updated October 21st 2022. Despite this announcement, 2310 other medical studies are currently recruiting patients to join their trials."

"This research initiative is seeking 245 individuals between the ages of 18 and 69 who are suffering from melancholia. In order to be considered, participants must meet additional criteria such as a diagnosis of moderate to severe major depressive disorder (MDD) or post-traumatic stress disorder (PTSD). Additionally, they should either not be taking an antidepressant medication or have been on one for at least 6 weeks without any dose modifications in the past 2 weeks. Furthermore, applicants need to commit to fulfilling all associated study assessments and procedures; this includes abstaining from pregnancy or breastfeeding during their enrollment period as well as throughout its duration."